Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | terminated | Phase 1 | 15 | Molecular Templates, Inc.INDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(VELIA) | terminated | Phase 3 | 1,140 | AbbVieINDUSTRY |
| 11 |
| Oct 26, 2024 |
| clinicaltrials |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04923672 | Exercise Preconditioning with Cancer Surgeries(ExPre 01) | terminated | N/A | 10 | University of VirginiaOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06068738 | Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian Cancer(EXCYTE-1) | terminated | — | 13 | Exscientia AI LimitedINDUSTRY | 2 | Sep 26, 2024 | clinicaltrials |
| NCT03493464 | BR55 in Characterization of Ovarian Lesions | terminated | Phase 2 | 14 | Bracco Diagnostics, IncINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03691376 | Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03644342 | Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix(NIVIX) | terminated | Phase 1 / Phase 2 | 4 | Michelle S LudwigOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT04248153 | Optimal Timing of BR55 CEUS of the Ovaries | terminated | Phase 2 | 3 | Bracco Diagnostics, IncINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04849858 | Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures | terminated | Phase 3 | 13 | University of California, IrvineOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | terminated | Phase 1 / Phase 2 | 89 | NantCell, Inc.INDUSTRY | 0 | Aug 20, 2024 | clinicaltrials |
| NCT04377087 | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer | terminated | Phase 2 | 3 | Sarah E TaylorOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | terminated | Phase 1 / Phase 2 | 79 | Elucida OncologyINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT03323398 | Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 79 | ModernaTX, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | NextCure, Inc.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT03439085 | DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers | terminated | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03367871 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | terminated | Phase 2 | 17 | University of MiamiOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | terminated | Phase 1 | 78 | ADC Therapeutics S.A.INDUSTRY | 3 | Jun 13, 2024 | clinicaltrials |
| NCT04004884 | Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)(LISA) | terminated | — | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | terminated | Phase 1 | 52 | ExelixisINDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | terminated | Phase 1 | 5 | Nurix Therapeutics, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05538624 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | terminated | Phase 1 / Phase 2 | 14 | Avenge Bio, IncINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT03128294 | Long Term Survivors in Ovarian Cancer | terminated | — | 69 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT05877404 | Practice Patterns Among Gynecologic Oncologists on Tumor Genetic Testing in Endometrial Cancer | terminated | — | 112 | Wake Forest University Health SciencesOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT03311334 | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Apr 18, 2024 | clinicaltrials |
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | terminated | N/A | 12 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04743999 | Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma | terminated | Phase 2 | 9 | Henry Ford Health SystemOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT00889733 | Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer(OVHM-01) | terminated | Phase 1 / Phase 2 | 9 | University Health Network, TorontoOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT01962948 | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | Fox Chase Cancer CenterOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT02574442 | Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer(Confocal) | terminated | — | 60 | British Columbia Cancer AgencyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03285841 | OCT-AF Imaging of Pre-cancers of Vulva and Cervix | terminated | — | 20 | British Columbia Cancer AgencyOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | terminated | Phase 1 | 31 | Mersana TherapeuticsINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05215496 | [18F]Fluoro-PEG-folate PET/CT Imaging in Epithelial Ovarian Cancer | terminated | Phase 1 | 5 | Lioe-Fee de Geus-Oei, MD PhDOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04718376 | A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer | terminated | Phase 1 | 56 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Mar 7, 2024 | clinicaltrials |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT04814875 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | terminated | Phase 1 / Phase 2 | 16 | THERAPIM PTY LTDINDUSTRY | 1 | Feb 14, 2024 | clinicaltrials |
| NCT04460807 | Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer(EXPERT) | terminated | Phase 3 | 23 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | terminated | N/A | 52 | University of WashingtonOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04864782 | QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer | terminated | Phase 2 / Phase 3 | 46 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 1, 2024source: clinicaltrials